---
document_datetime: 2025-09-26 16:52:38
document_pages: 5
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/tigecycline-accord-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: tigecycline-accord-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 19.9182217
conversion_datetime: 2025-12-28 14:27:20.174429
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Tigecycline Accord

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency' s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessmenthistory'section.Forthe completeproduct lifecycleprocedures,you mayneedtoalsorefertoEPAR-Proceduralsteps taken andscientific information after authorisation (archive).

| Applicationnumber    | Scope                                  | Opinion/ Notification 1 issued on   | Commission Decision IssuedÂ²/ amendedon   | Product Information affected3   | Summary   |
|----------------------|----------------------------------------|-------------------------------------|------------------------------------------|---------------------------------|-----------|
| Variation typeIA_IN/ | This was an application for a group of | 25/09/2025                          |                                          | Annex II and                    |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000300796                     | variations. B.II.b.2.cReplacement or addition of a manufacturerresponsibleforimportation and/orbatch release-B.11.b.2.c.2Including batch control/testing-Accepted B.II.b.1Replacement or addition of a manufacturingsiteforpartor all of the manufacturing process of the finished product - B.1I1.b.1.a Secondary packaging site - Accepted                                                                                                                                                                                     |            |     | PL   |
|---------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|------|
| Variation type IB / EMA/VR/0000285855 | Thiswas an applicationfor a group of variations. B.II1.1.a European Pharmacopoeial Certificate of Suitability to the relevant Ph. Eur. Monograph - B.1I1.1.a.2 Updated certificate from an already approved manufacturer-Accepted B.I.b.1 Change in the specification parameters and/or limits of an active substance,startingmaterial/intermediate/ reagentused in themanufacturingprocess oftheactivesubstance-B.I.b.1.cAddition ofanewspecificationparametertothe specification with its corresponding test method - Accepted | 31/07/2025 | N/A |      |

<div style=\"page-break-after: always\"></div>

| substance or starting material/reagent/intermediateused in the manufacturing process of the active substance-B.I.b.2.aMinorchangestoan approved test procedure - Accepted B.1.b.2Changein testprocedureforactive substance or starting material/reagent/intermediate used in the manufacturingprocess of the active substance-B.I.b.2.a Minor changes to an approved test procedure - Accepted B.III1.1.a European Pharmacopoeial CertificateofSuitabilitytotherelevantPh. Eur. Monograph - B.1I1.1.a.2 Updated certificate from an already approved manufacturer-Accepted B.III.1.aEuropeanPharmacopoeial CertificateofSuitability totherelevantPh. Eur.Monograph-B.II1.1.a.2 Updated certificate from an already approved manufacturer-Accepted B.Ill.1.aEuropeanPharmacopoeial CertificateofSuitability totherelevantPh. Eur.Monograph-B.II1.1.a.2 Updated certificate from an already approved   |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

| Variation type IB / EMA/VR/0000273034   | C.IHUMANANDVETERINARYMEDICINAL PRODUCTS-C.I.zImplementation of an agreed wording, no new data submitted - Accepted C.I.z-Toupdatesection5.1of theSmPC in linewiththe\"Guidelineontheevaluationof medicinalproductsindicatedfortreatment of bacterialinfections\"published ontheEMA website.Furthermore,the MAH has taken the opportunity to update section 9 of the SmPCwiththedateoflatestrenewal:25 November2024.Inaddition,theMAHhas takentheopportunitytoupdatethedetails of the local representative for Greece in the package leaflet.   | 05/06/2025   |     | SmPC and PL   |
|-----------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-----|---------------|
| Variation type IA / EMA/VR/0000265607   | B.II.d.2 Change in test procedure for the finishedproduct-B.II.d.2.aMinor changes toan approved testprocedure-Accepted                                                                                                                                                                                                                                                                                                                                                                                                                       | 15/04/2025   | N/A |               |
| Variation type IA / EMA/VR/0000244119   | C.IHUMANANDVETERINARYMEDICINAL PRODUCTS - C.I.z Change(s) in the SmPC, labellingorpackageleafletofhuman medicinalproductsinordertoadapttoa recommendation of a competent authority , e.g. a Core SmPC, following the assessment of an Urgent Safety Restriction etc. Implementationofwording agreedbythe competent authority that require additional minor assessment, e.g. translations are not yet agreedupon.-Refused                                                                                                                     | 23/01/2025   | N/A |               |

<div style=\"page-break-after: always\"></div>